戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 immune cells with a highly immunosuppressive antineoplastic drug.
2 her optimization to develop a c-Myc-targeted antineoplastic drug.
3 so induced partial cross-resistance to other antineoplastic drugs.
4  making the tumor cells further resistant to antineoplastic drugs.
5 ity and alter the pharmacokinetic profile of antineoplastic drugs.
6 ffects of reactive oxygen species-generating antineoplastic drugs.
7 lective, small-molecule kinase inhibitors as antineoplastic drugs.
8 ng strategies as a means of developing novel antineoplastic drugs.
9 c target for a number of clinically relevant antineoplastic drugs.
10 clinical studies of anti-HER2 SL loaded with antineoplastic drugs.
11 to improve the development and evaluation of antineoplastic drugs.
12 thers to cell death when combined with other antineoplastic drugs.
13 ys a crucial role in multidrug resistance to antineoplastic drugs.
14 fer improved bone integration and release of antineoplastic drugs.
15 ophore in many antiviral, antimicrobial, and antineoplastic drugs.
16 pramolecular capabilities for the loading of antineoplastic drugs.
17 ures impacted recent regulatory approvals of antineoplastic drugs.
18 gest a potential role for S-nitrosylation in antineoplastic drug action.
19 late kinase is involved in antimicrobial and antineoplastic drug activation.
20 nged exposure of lung-resident tumors to the antineoplastic drug and reduced local toxicity.
21 ifferences in cancer across four key topics: antineoplastic drugs and responses (SDR), oncology-relat
22 pression also modulates the effects of other antineoplastic drugs and whether it is associated with a
23 gnosis of involved biomarkers and delivering antineoplastic drugs are under either clinical trials or
24 ay be most useful when "metronomic" doses of antineoplastic drugs are used, thereby potentially avoid
25 tudy, we monitored the cellular responses to antineoplastic drug at a single cell basis with Raman sp
26                                We found that antineoplastic drugs become concentrated in specific pro
27               Exisulind (Aptosyn) is a novel antineoplastic drug being developed for the prevention a
28 nvolved in the metabolic inactivation of the antineoplastic drug bleomycin.
29 nt studies have shown that some conventional antineoplastic drugs can be exploited for antiangiogenic
30 tential to augment preclinical evaluation of antineoplastic drug candidates for these malignancies.
31                                          The antineoplastic drug carmofur is shown to inhibit the SAR
32                        Here we show that the antineoplastic drug carmofur, which is used in the clini
33 effectively treat gliomas by reaching a high antineoplastic drug concentration at the target site wit
34                               Carmofur is an antineoplastic drug containing an electrophilic carbonyl
35 ationale can be proposed for intraperitoneal antineoplastic drug delivery in non-ovarian malignant di
36 l modulation of BTB permeability to increase antineoplastic drug delivery selectively to brain tumors
37 ransferases (GSTs) in cellular resistance to antineoplastic drugs, derivatives of MCF7 breast carcino
38  has been proposed as a potential target for antineoplastic drug design.
39 is has recently become a suitable target for antineoplastic drug development.
40 y may contain molecular targets suitable for antineoplastic drug discovery.
41  has served as an important lead compound in antineoplastic drug discovery.
42 rmacogenomics in which ethnic differences in antineoplastic drug disposition are anticipated.
43             Doxorubicin (Dox), a cardiotoxic antineoplastic drug, disrupts the cardiac-specific progr
44  We have investigated the ability of another antineoplastic drug, dolastatin 10, in inducing Bcl2 pho
45 I) chloride hexahydrate (CoCl2.6H2O) and the antineoplastic drug doxorubicin.
46  The therapeutic efficacy of the widely used antineoplastic drugs doxorubicin, cisplatin, vincristine
47                                              Antineoplastic drugs following platinum-based chemothera
48       Procedures to regulate the ordering of antineoplastic drugs for nonmalignant indications by non
49 dentification, optimization and synthesis of antineoplastic drugs from PnV molecules may lead to a ne
50                                  A myriad of antineoplastic drugs from vascular endothelial growth fa
51    Nortriptyline further synergizes with the antineoplastic drug gemcitabine to effectively suppress
52                            Prices of topical antineoplastic drugs had the greatest mean absolute and
53 on drug class, and show the emerging role of antineoplastic drugs in the field of drug-induced myocar
54      Moreover, the local toxicity induced by antineoplastic drugs is considered a major obstacle for
55 en paracrine IL-2 and local i.c. delivery of antineoplastic drugs is novel and may provide a combined
56  side effect associated with cancer-treating antineoplastic drugs is the development of neuropathic p
57         The efficacy of ifosfamide (IFO), an antineoplastic drug, is severely limited by a high incid
58                            Several important antineoplastic drugs kill cells by increasing levels of
59                                         Many antineoplastic drugs kill tumor cells by inducing apopto
60  antisense ODNs in combination with standard antineoplastic drugs might be useful in reversing MDR in
61 positions tend to have worse response to six antineoplastic drugs predicted by a lncRNA-based Elastic
62 rom the National Cancer Institute's In Vitro Antineoplastic Drug Screen to assess whether sensitivity
63 tructurally disparate DNA cleavage-enhancing antineoplastic drugs share an overlapping site of action
64            Ethonafide is an anthracene-based antineoplastic drug similar to MIT.
65            ABCG2 expression was sensitive to antineoplastic drugs since exposure to 5 muM doxorubicin
66                                          The antineoplastic drug sorafenib (BAY 43-9006) is a multiki
67                                              Antineoplastic drugs such as mitomycin C (MMC) and inter
68  erythroleukemia K562 cells are resistant to antineoplastic drug (taxol)-induced apoptosis through th
69 n over the past decade, yet most preclinical antineoplastic drug testing is still reliant on conventi
70 hypersensitivity of HAP1 to camptothecin, an antineoplastic drug that stabilizes topoisomerase I clea
71 Microtubule-damaging agents (MDA) are potent antineoplastic drugs that are widely used in clinical tr
72                 It is also a target for many antineoplastic drugs that promote stabilization of coval
73 witch is a rational target for the design of antineoplastic drugs that selectively inhibit PKCepsilon
74 at, when FTI is combined with some cytotoxic antineoplastic drugs, the effects on tumor cells are add
75  and the most commonly fatal complication of antineoplastic drug therapy and may represent a serious
76 he nucleoside analogue floxuridine, a potent antineoplastic drug used in the clinic to treat advanced
77 Arabinofuranosylcytosine (Ara-C) is a potent antineoplastic drug used in the treatment of acute leuke
78  effect of difopein on cell death induced by antineoplastic drugs was examined.
79        Paclitaxel is a microtubule-targeting antineoplastic drug widely used in human cancers.
80                       Paclitaxel (PTX) is an antineoplastic drug widely used in treatments for ovaria
81 ristol-Myers Squibb, Princeton, NJ) is a new antineoplastic drug with broad-spectrum activity in soli
82 trophy) as well as in chemotheraputic use of antineoplastic drugs with cardiotoxic side effects (i.e.